Drug Profile
Research programme: anti-cancer therapeutics - Sorrento Therapeutics
Alternative Names: Anti-CD123 CAR-T cells; Anti-CD38 CAR-T cells; Anti-HAVCR2 mAbs - Sorrento; Anti-PD-1 mAbs - Sorrento Therapeutics; Anti-PD-L1 mAbs - Sorrento Therapeutics; Anti-TIM3 mAbs- Sorrento Therapeutics; CAR-T - TNK Therapeutics; CAR-T c-KIT; CAR-T GD3; CAR-T IL13R; STI 1110; STI-A0168; STI-A020X; STI-A050X; STI-A060X; STI-A1010; STI-A1011; STI-A1012; STI-A1110; T-007; T-009Latest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator BDL Products, Inc.; CARgenix Holdings LLC; Sorrento Therapeutics
- Developer Sorrento Therapeutics; TNK Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD38 antigen inhibitors; Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists; Ganglioside inhibitors; HAVCR2 protein inhibitors; Interleukin 13 expression modulators; Interleukin 13 inhibitors; Interleukin-3 receptor alpha subunit antagonists; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Cancer; Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 28 Jan 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)